ISRCTN70702834已完成3 期
A phase 3 randomised, rater- and dose-blinded study comparing two annual cycles of intravenous low- and high-dose alemtuzumab to three-times weekly subcutaneous interferon beta-1a (Rebif®) in patients with relapsing-remitting multiple sclerosis who have relapsed on therapy
Genzyme Corporation (USA)0 个研究点目标入组 700 人开始时间: 2009年3月11日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 700
研究概览
简要总结
2012 results in: http://www.ncbi.nlm.nih.gov/pubmed/23122650
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Amended as of 24/06/2009:
- •Point 7 has been removed from the below inclusion criteria.
- •Initial information at time of registration:
- •1. Males and females, aged 18 - 55 years old
- •2. Diagnosis of MS and MRI scan demonstrating white matter lesions attributable to MS
- •3. Onset of MS symptoms within 10 years of screening
- •4. Expanded Disability Status Scale (EDSS) score 0.0 to 5.0
- •5. Greater than or equal to 2 MS attacks within 24 months, with greater than or equal to 1 attack within 12 months
- •6. Greater than or equal to 1 MS attack (relapse) during treatment with a beta interferon therapy or glatiramer acetate after being on that therapy for at least 6 months within 10 years
- •7. Neurologically stable for the 30 days prior to the date the Informed Consent Form is signed
排除标准
- •1. Previous treatment with alemtuzumab
- •2. Previous treatment with any investigational drug (i.e. medication that is not approved at any dose for any indication)
- •3. Treatment with natalizumab, methotrexate, azathioprine or cyclosporine in the past 6 months
- •4. Previous treatment with mitoxantrone, cyclophosphamide, cladribine, rituximab, or any other immunosuppressive, or cytotoxic therapy (other than steroid treatment)
- •5. Any progressive form of MS
- •6. Any disability acquired from trauma or another illness that could interfere with evaluation of disability due to MS
- •7. Major systemic disease that cannot be treated or adequately controlled by therapy
- •8. Active infection, or high risk for infection
- •9. Autoimmune disorder (other than MS)
- •10. Impaired hepatic or renal function
- •11. History of malignancy, except basal skin cell carcinoma
- •12. Medical, psychiatric, cognitive, or other conditions that compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol, or to complete the study
- •13. Known bleeding disorder
- •14. Of childbearing potential with a positive serum pregnancy test, pregnant, or lactating
- •15. Current participation in another clinical study or previous participation in CAMMS323 (registered with ISRCTN21534255)
- •16. Previous hypersensitivity reaction to any immunoglobulin product
- •17. Known allergy or intolerance to interferon beta, human albumin, or mannitol
- •18. Intolerance of pulsed corticosteroids, especially a history of steroid psychosis
- •19. Inability to self-administer subcutaneous (SC) injections or receive SC injections from caregiver
- •20. Inability to undergo MRI with gadolinium administration
- •21. Unwilling to use a reliable and acceptable contraceptive method throughout the study period (fertile patients only)
研究者
相似试验
已完成
3 期
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study OneMultiple sclerosisNervous System DiseasesISRCTN21534255Genzyme Corporation (USA)581
已完成
3 期
Safety and efficacy trial of two doses of lurasidone in acutely psychotic subjects with schizophrenia (PEARL 3)Mental and Behavioural DisordersSchizophreniaISRCTN64695913Dainippon Sumitomo Pharma America Inc. (USA)480
已完成
不适用
2x2 factorial randomised phase III study comparing standard versus whole bladder volume radiotherapy with and without synchronous chemotherapy in muscle invasive bladder cancerBladder (advanced)CancerISRCTN68324339Individual Sponsor (UK)458
撤回
3 期
CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic DermatitisAtopic DermatitisNCT05614817Suzhou Connect Biopharmaceuticals, Ltd.
已完成
3 期
SORCE: a phase III randomised double-blind study comparing SOrafenib with placebo in patients with Resected primary renal CEll carcinoma at high or intermediate risk of relapseRenal cell carcinomaPrimary renal cell carcinomaCancerISRCTN38934710Medical Research Council (UK)1,711